E-Star BioTech Initiates Phase 2 Trial of MANP for Resistant Hypertension Treatment
• E-Star BioTech has dosed the first patient in its BOLD-HTN Phase 2 clinical trial, evaluating MANP for resistant hypertension treatment, marking a significant milestone in cardiovascular medicine.
• The company's MANP therapy, licensed from Mayo Clinic, has shown promising safety profiles in multiple Phase 1 studies involving patients with hypertension and cardiometabolic syndrome.
• With global hypertension affecting 1.28 billion adults and only 21% achieving proper control, this trial addresses a critical unmet medical need in cardiovascular health management.
© Copyright 2025. All Rights Reserved by MedPath